Phase II trial of HLA [human leukocyte antigen] haploidentical natural killer cell infusion [cell-therapies] for treatment of relapsed or persistent leukemia following allogeneic hematopoietic stem cell transplant.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Cytarabine; Fludarabine
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Feb 2016 Biomarkers information updated
- 05 Feb 2013 Planned end date changed from 1 Dec 2010 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 29 Nov 2012 New source identified and integrated (Memorial Sloan-Kettering Cancer Center; 07-035)